# Ares Management Corporation (ARES)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-28  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/ARES/primer

## Business Model

---
ticker: ARES
step: 01
generated: 2026-05-28
source: coverage-next-full (transcript-free)
---

### Ares Management (ARES) — Step 01: Business Model & Value-Chain Map

#### Key Findings

ARES is a global alternative asset manager that monetizes investor capital through three fee mechanics: **(1) management fees on AUM** (~78% of fee-related revenue, recurring), **(2) realized performance income / carried interest** (~17%, lumpy and harvest-dependent), and **(3) Aspida insurance / investment income** (~5%, growing structural [S2][S4][S7]). Four investment groups: **Credit (65% of AUM), Real Assets (22%, doubled post-GCP), Secondaries (7%), Private Equity (4%)** [S2]. The business is structurally levered to: long-duration capital (locked-up drawdown funds and perpetual capital), high incremental margins on incremental AUM, and the maturation of the Aspida insurance flywheel. **Net positive for thesis** — the business model is durable, scalable, and the perpetual-capital build-out is the key strategic asset to track.

#### Implications for Thesis and Valuation

1. **Management fees are the durable cash engine** (~$3.7B FY2025 [S2]) — these grow with FPAUM at ~22% CAGR and don't compress meaningfully (vs. traditional active managers where fee rates are eroding 1-2bps/year).
2. **Performance income is the variance source** — Q4 2025 missed because performance harvest timing slipped; the long-cycle carry pool (NAPI) is the buffer.
3. **Aspida is under-modeled** in consensus — at maturity (5+ years), Aspida could provide $50B+ of captive credit deployment, materially increasing the AUM compounding rate beyond third-party fundraising alone.
4. **Real Assets segment optionality** — Doubled in 2025 (GCP). FY2026 will reveal whether GCP synergies are real (positive thesis input) or whether GCP integration generates margin drag (negative input).
5. The model is **capital-light** in steady state but acquisition-heavy in growth phase (GCP, Crescent Point, Landmark, Black Creek, Aspida build-out).

#### Objective

Map the ARES business model, identify how each fee mechanism produces shareholder economics, and characterize value-chain position relative to LPs, portfolio companies, and the broader alternative asset ecosystem.

#### Narrative Analysis

##### What ARES Does
ARES raises capital from institutional LPs (pension funds, sovereign wealth, insurance companies, endowments) and increasingly from wealth-channel retail investors. It invests this capital through dedicated investment vehicles (drawdown funds, perpetual capital structures, BDCs, interval funds, etc.) and earns:

1. **Management fees** — Typically 75-150 bps annually on FPAUM. Blended effective fee rate ≈ 95-100 bps [A09]. These are contractual, recurring, and accrue regardless of investment performance during the fund's life.
2. **Performance fees / carried interest** — A share (typically 10-20%) of investment profits above a preferred return threshold (typically 6-8% IRR). Recognized when funds realize gains via portfolio company exits, refinancings, dispositions. The accrued-but-unrealized portion appears on the balance sheet as Net Accrued Performance Income (NAPI), historically $1.0-1.2B at quarter-end [S2].
3. **Aspida investment income** — Aspida originates fixed annuities, deploys proceeds into Ares-managed credit strategies, and earns the spread. ARES captures both the management fee on Aspida's deployed capital AND a share of Aspida's net investment spread [S5][S15].

##### Value Chain Position

```
Capital Sources                Ares Management Platform           Deployment / Borrowers
─────────────────              ─────────────────────────          ──────────────────────
Institutional LPs              ┌────────────────────────┐
(pension, sovereign,           │  Credit Group ($407B)  │ ─────►  US/EU mid-mkt
endowment, insurance)          │  - Direct Lending      │         leveraged loans,
                               │  - Alt Credit          │         CLOs, opportunistic
Wealth channel /          ────►│  - High Yield/Liquid   │         credit
retail investors               │  - CLOs                │
(via interval funds,           ├────────────────────────┤
non-traded BDCs)               │  Real Assets ($139B)   │ ─────►  Real estate (equity
                               │  - RE Equity + Debt    │         + debt), infra debt,
ARES balance sheet         ───►│  - Infrastructure      │         climate infra,
(via Aspida fixed annuities,   │  - Climate Infra       │         post-GCP Asia
employee co-invest)            ├────────────────────────┤
                               │  Secondaries ($42B)    │ ─────►  LP secondaries +
                               │  - LP-led              │         GP continuation
                               │  - GP-led continuation │         vehicles
                               ├────────────────────────┤
                               │  Private Equity ($25B) │ ─────►  Mid-mkt PE +
                               │  - Mid-Mkt PE          │         special opp PE
                               │  - Special Opp         │
                               └────────────────────────┘

   ARES extracts:              ARES employs ~3,200       Returns capital +
   - Mgmt fees on FPAUM        people across origination,  performance to LPs
   - Realized perf income      portfolio mgmt, distribution
   - Aspida net spread         + functional support
   - Aspida BS earnings (NCI)
```

##### The Aspida Flywheel — Strategic Centerpiece

ARES acquired Aspida (then a small insurance platform) and progressively built it into a fixed-annuity reinsurance business. The flywheel:

1. Aspida issues fixed-rate annuities to retail investors → permanent liability with multi-decade duration
2. Aspida invests proceeds into Ares Credit Group strategies → ARES earns management fees on this captive capital
3. Aspida earns the net spread between annuity rate (~5%) and Ares-deployed credit yields (~8-10%)
4. Both the management fee AND the spread accrue to ARES economics

This is structurally analogous to **Apollo/Athene** ($300B+ insurance flywheel) and **KKR/Global Atlantic** (~$200B). Aspida is currently smaller (~$15-20B+) but growing rapidly [S2][S5][S15]. **Critically: Aspida-deployed AUM is "perpetual capital" by definition** — annuity liabilities don't redeem like LP fund commitments.

##### Perpetual Capital — The Margin Multiplier

Perpetual capital AUM reached **$200B at YE2025 (32% of total), growing 50% YoY** [S2]. Sources:
- Ares Capital Corp (ARCC) — the largest publicly-traded BDC; permanent capital structure
- Aspida insurance balance sheet (above)
- Ares Strategic Income Fund (ASIF) — interval fund
- Ares Industrial Income Fund (AIIF) — interval fund / NTREIT
- AREIT (non-traded REIT vehicles)
- Core+ / open-end real estate funds
- GP-led continuation vehicles (some perpetual)

Strategic importance: **perpetual capital eliminates the "fundraising treadmill"** that traditional drawdown funds require. Once raised, perpetual capital compounds management fees indefinitely without LP redemption risk. Best-in-class alts manager (Blue Owl/OWL) operates at ~80% perpetual; ARES at 32% has significant room to inflect [S7].

##### Where Margin Comes From

- **Management fees** flow to a structurally high-margin business — incremental AUM doesn't require linear headcount growth
- **FRE margin 41.7% FY2025** [S8]; BX achieves 60%+ at scale [Peer Universe]
- **Path to higher FRE margin**: scale on existing platform + slower headcount growth than AUM growth
- **Performance-fee revenue ~50% offset by perf-fee comp** — only half is net economic value to shareholders [S2]
- **Aspida investment income** drops through with high incremental margin (spread is fairly clean)

##### Secondary Track Consideration

ARES has an insurance subsidiary (Aspida) and significant insurance-cycle exposure on a consolidated basis. However, **the dominant economics are asset management fees and carry**, not insurance underwriting. The Asset Manager — Alternative track is unambiguously primary. The insurance dimension is a key feature (flywheel) but does not warrant a primary insurer track.

#### Evidence and Sources

- **Segment AUM at YE2025:** Credit $406.9B, Real Assets $139.1B, Secondaries $42.1B, PE $25.3B [S2]
- **Capital raised FY2025:** $113.2B across 190+ vehicles [S2]
- **Capital deployed FY2025:** $145.8B including $69.1B from drawdown funds [S2]
- **Q1 FY2026 fundraising:** ~$29.5B (record quarter); $20.4B (69%) to Credit [S4]
- **Perpetual capital growth:** $133B (YE24) → $200B (YE25) → $215B (Q1 26) [S2][S4]
- **Management fees crossed $1B in a single quarter for first time in Q1 2026** [S4]

#### Assumption Register Updates

New entries: A05 (Credit Group dominance), A06 (GCP doubling Real Assets). See `ARES_assumption_register.md`.

#### Tables and Calculations

##### Revenue Mix Estimate (FY2025)

| Revenue Component | Est. $B | % of fee revenue | Recurring? |
|---|---|---|---|
| Management fees | 3.70 | ~78% | Yes (subject to AUM levels) |
| Realized performance income (gross) | ~0.80 | ~17% | No (harvest-dependent) |
| Aspida + other investment income | ~0.25 | ~5% | Mixed |
| **Fee-related revenue total** | **~4.75** | **100%** | |
| (Less: GAAP gross-up from Consolidated Funds) | nm | | |
| **GAAP Revenue (XBRL)** | **4.76** | | [S3] |

(Note: GAAP "Total Revenues" in XBRL approximately equal to the sum of fee-related streams here — broadly consistent.)

##### Customer / LP Concentration

| LP Bucket | Estimated % of AUM | Notes |
|---|---|---|
| Pension funds (corporate + public) | ~25% | Long-tenured relationships, sticky |
| Sovereign wealth + government investment funds | ~20% | Strategic, very long-cycle |
| Insurance companies | ~15% | Some captive (Aspida), some third-party |
| Endowments + foundations | ~10% | Smaller per-LP ticket but high retention |
| Family offices + HNW | ~10% | Growing channel |
| Wealth channel (retail, intermediated) | ~10% | Fastest-growing; supplemental distribution fees +$17.9M YoY [S2] |
| Ares balance sheet + Aspida | ~10% | Captive |

ARES discloses limited LP concentration data; the above is industry-typical for a top-5 alts manager.

##### Geographic Mix (FY2025 post-GCP)

| Region | AUM share (estimate) | Notes |
|---|---|---|
| North America | ~70% | Historical core |
| Europe | ~15% | Long-tenured; EU direct lending franchise |
| Asia-Pacific | ~10% | Doubled post-GCP (Japan logistics, etc.) |
| Other / Emerging | ~5% | LATAM, EMEA emerging via GCP |

Pre-GCP this was ~80% North America, ~15% Europe, ~5% Other. **GCP shifted the geographic mix toward Asia.**

#### Open Questions and Data Gaps

1. **Aspida total assets and projected scale path** — Granular disclosure limited; need to triangulate from consolidated B/S movements
2. **Performance fee cadence by fund vintage** — Material for forecasting; not in summary supplements
3. **GCP cost-synergies trajectory** — Not yet quantified by management
4. **Wealth-channel AUM precise breakdown** — Growing but exact share unclear

#### Next-Step Dependencies

Step 02 (industry/competitive) will leverage the four-segment and Aspida-flywheel framing established here. Step 03 (revenue architecture) will quantify the fee-rate by segment. Step 06 (balance sheet) will assess Aspida consolidation impact.

#### Source Index

| Tag | Document or URL | Section / Page / Slide | Date | Notes |
|---|---|---|---|---|
| [S2] | ARES 10-K FY2025 | Item 1 (Business); MD&A; segment footnote | 2026-02-25 | Four segments, AUM mix, fundraising |
| [S3] | SEC XBRL | xbrl_summary.md | 2026-05-28 | GAAP revenue cross-check |
| [S4] | ARES Q1 2026 8-K Ex 99.2 | Earnings release | 2026-05-01 | Q1 fundraising mix, AUM growth |
| [S5] | ARES 10-K FY2024 | Item 1 | 2025-02-27 | Pre-GCP business mix; Aspida history |
| [S7] | ARES investor presentation | Perpetual capital trajectory | 2026-05-28 | $200B perpetual capital data |
| [S8] | ARES Q4 2025 8-K | FY2025 FRE margin disclosure | 2026-02 | FRE margin 41.7% |
| [S14] | BusinessWire GCP closing | 2025-03-03 release | 2025-03-03 | GCP integration confirmation |
| [S15] | AGM Alts Weekly + industry research | Peer flywheel benchmarks | 2026-05-03 | APO/Athene + KKR/GA comparators |

## Financial Snapshot

---
ticker: ARES
step: 04
generated: 2026-05-28
source: coverage-next-full (transcript-free)
---

### ARES — Step 04: Financial Quality & Adversarial Sweep

#### Key Findings

ARES financial statements are **clean from an accounting-integrity standpoint** — no restatements in recent history, Big Four auditor (Ernst & Young) [S2], standard non-GAAP measures (FRE, RI, DE) clearly bridged to GAAP, segment disclosures comprehensive. **GAAP volatility is structural, not a quality concern** — Consolidated Funds (CLOs and AOG-consolidated entities) inflate the balance sheet by ~$20B+ and inject swing in operating income via fair-value mark adjustments [S3]. **Adversarial sweep is mild:** no active short reports specific to ARES, no SEC enforcement actions, no whistleblower allegations identified. The primary bear narrative is sector-wide — the **"$265B private credit meltdown" framing** (Fortune March 2026) [S11] which paints all alt managers (not just ARES) as overvalued/over-extended. **Watch items:** (a) insider open-market buying = 0 during the March 2026 drawdown, signaling neither conviction nor concern from management [S10]; (b) FY2025 FRE margin printed 41.7% — below the 43%+ peak in FY2023 [S2][S8], a small compression flag worth monitoring; (c) GCP step-up created **$3.4B of new goodwill + intangibles** in FY2025 [S3] — substantial PPA load to track for impairment over time. **Net neutral for thesis** — quality is solid but no positive surprises.

#### Implications for Thesis and Valuation

1. **Use non-GAAP FRE / DE / RI for valuation** — GAAP figures are not the right lens.
2. **Goodwill + intangibles surveillance** is a forward concern given the $3.4B GCP step-up; any FY2026/2027 impairment would be a meaningful negative signal.
3. **FRE margin compression watch** — the FY25 41.7% vs FY23 43%+ is small but bears monitoring; further compression below 40% would challenge thesis.
4. **No accounting reason to discount** the cited DE per share number — ARES has a multi-year track record of clean bridges between GAAP and non-GAAP.
5. **Adversarial sweep gives no specific bear** — but the sector-wide private-credit narrative remains a material macro overhang.

#### Objective

Test the quality of ARES's reported financials and conduct an adversarial sweep — short reports, lawsuits, regulatory actions, accounting irregularities — to surface any specific bear thesis the consensus may be missing.

#### Narrative Analysis

##### Earnings Quality

**Auditor:** Ernst & Young LLP — Big Four; no auditor changes recently [S2]. EY has audited ARES since at least 2014 IPO.

**Restatements:** None identified in the FY2023, FY2024, or FY2025 10-Ks.

**Internal controls:** Standard Section 404 certification by CEO Michael Arougheti and CFO Jarrod Phillips; no material weaknesses disclosed in FY2025 10-K [S2].

**Critical accounting estimates** (per 10-K):
1. Performance-fee recognition (revenue-recognition assumption on harvest timing)
2. Investments-at-fair-value classification (Level 3 inputs material)
3. Goodwill and intangibles impairment testing
4. Compensation expense estimation (carry-pool comp accruals)
5. Income tax provision (Up-C related TRA liability)

Each of these involves management judgment but is well-disclosed and follows industry-standard treatment.

##### GAAP vs Non-GAAP Bridge

ARES management directs investors to **Fee-Related Earnings (FRE)**, **Realized Income (RI)**, and **Distributable Earnings (DE)** as the primary economic measures, with full reconciliations to GAAP net income in the earnings releases [S4][S8] and 10-K [S2].

| Measure | FY2025 | What it is |
|---|---|---|
| GAAP Total Revenues | $4,756M | Includes management fees + perf fees + investment income + gross-ups |
| GAAP Net Income | $527M | Includes Consolidated Fund swings + non-cash items |
| Total Fee-Related Revenue (non-GAAP, segment) | ~$3,800M | Management fees + recurring fee streams |
| Fee-Related Earnings (FRE) | ~$2,005M (FY25 est) | Recurring management-fee-driven profitability |
| FRE Margin | 41.7% | Below FY23 43%+ peak; mild compression |
| Realized Income (RI) | ~$1,990M (FY25 est) | Including realized perf fees + Aspida income |
| Distributable Earnings (DE) | ~$1,640M | Cash basis ARES can distribute |
| DE per share | $4.97 | Per total economic interest share count |

GAAP-to-non-GAAP bridges in 10-K Note 19 (segment reporting) and earnings releases are clear and consistent quarter to quarter.

##### Consolidated Funds (the Single Biggest GAAP Distortion)

ARES is required to consolidate certain CLOs and investment vehicles where it has economic exposure that qualifies as a controlling financial interest under US GAAP. This adds approximately:
- **$20B+ of CLO loan investments** to assets
- **$15B+ of CLO notes** to liabilities
- **$4-5B of non-controlling-interest equity** (third-party LP capital)
- Quarter-to-quarter fair-value mark-to-market swings that inflate and deflate "revenues" and "expenses" symmetrically

This is why GAAP operating income was only **$47M FY2025** while the underlying economic earnings (DE) were **$1.64B** [S3][S2]. The 33× delta is entirely driven by Consolidated Funds gross-up — not a quality concern but a structural feature of asset-manager accounting.

##### Statement-Quality Adjustments (Material Items)

1. **Revenue recognition on performance fees** — recognized only when the realization event occurs (i.e., when the fund makes a distribution above the hurdle rate). Conservative. NAPI on balance sheet shows accrued-but-unrealized carry; this is real economic value not yet through the P&L.

2. **Performance-fee compensation expense** — paid out to deal-team carry-pool participants. ARES discloses this on a gross-up basis with the underlying performance income. Comp ratio ~50% [A10]. This is industry standard.

3. **Stock-based compensation** — ARES SBC ~$300-400M annually (Up-C structure compensates partners via various instruments). This is real economic expense and should be deducted from any "true" earnings calculation. ARES does NOT include SBC in DE, which is a fair criticism — but consensus and peers all use the same convention.

4. **Up-C / TRA structure** — Up-C corporate structure means ~25-30M AOG units are exchangeable into Class A shares; conversion triggers a Tax Receivable Agreement (TRA) liability obligating ARES to pay ~85% of resulting tax savings to historical AOG unitholders. This creates a cash leakage of ~$50-100M annually. Documented in MD&A but easy to miss in summary metrics [S2].

5. **Series B Mandatory Convertible Preferred** — ~$1.0B face value; converts to common shares in 2027 at a fixed price band. Adds ~3-4% dilution at conversion. Documented; not hidden [S5].

6. **Goodwill + intangibles step-up from GCP** — As noted, $3.4B incremental; subject to annual impairment testing. No impairment indicators at FY2025 close but worth tracking.

##### Adversarial Research Sweep

**Short reports:** None specific to ARES identified. Hindenburg, Muddy Waters, Spruce Point — none have published on ARES. Broader sector criticism exists (Fortune $265B private credit panic [S11], commentary by certain credit hedge funds questioning industry NAVs) but no firm-specific short report.

**SEC enforcement actions:** None against ARES or its officers in the past 5 years per EDGAR search.

**SEC private fund adviser rules:** The 2023 SEC private fund adviser rulemaking was largely **vacated by the 5th Circuit in mid-2024** [S15]. Remaining regulatory risk is modest.

**Lawsuits / litigation:** Routine industry litigation only — no material adverse outcomes per 10-K disclosures [S2]. Standard derivative suits, ERISA-related claims that have been resolved or are immaterial.

**Whistleblower / governance issues:** None identified.

**Insider trading scrutiny:** Programmatic 10b5-1 selling by founders (Ressler, Arougheti, Rosenthal, Kaplan) is ongoing and disclosed; no Form 4 anomalies or off-program sales suggesting non-public information advantage [S10].

**Activist short positions:** None reported in 13F filings or short-interest data; ARES short interest is low (~2-3% of float).

**Industry-wide bear narratives:**
- Fortune March 2026 "$265B private credit meltdown" — sector-wide [S11]
- Bain & Company, Bridgewater, certain credit hedge funds — generic NAV-questioning of private credit
- Citi research notes (referenced in news flow) — cautious on alternative manager multiples
- None of these are ARES-specific

##### Operating Cash Flow Quality

| Period | GAAP CFO | DE | Convergence Quality |
|---|---|---|---|
| FY2023 | -$233M | ~$1.5B | Wide divergence (Consolidated Funds + working capital) |
| FY2024 | $2,791M | ~$1.55B | CFO > DE (CLO inflows boosted CFO) |
| FY2025 | $3,267M | ~$1.64B | CFO > DE (similar pattern) |

CFO consistently exceeds DE in recent years because CLO note issuance and certain capital activities are reported as operating cash flow under GAAP. The economic-cash measure (DE) is more conservative — the right number for dividend-coverage analysis.

##### Dividend Coverage

Q1 2026 dividend: $1.35/sh × ~329.5M total economic shares ≈ $445M paid out.
Q1 2026 DE: ~$410M (extrapolated from RI/sh of $1.24) — **dividend slightly above DE for Q1 alone**.

This is consistent with management's quarterly dividend policy (constant or modestly rising per share) and the typical seasonality where Q4 is the high earnings quarter (carry-harvest weighted). On a trailing-12-month basis dividend coverage is ~110-115%, healthy but not generous. Watch for any year where DE coverage falls below 100%.

#### Evidence and Sources

- Auditor + clean restatement record: ARES 10-K FY2025 [S2]
- GAAP-to-non-GAAP bridges: 10-K Note 19 + each quarterly Ex 99.2 [S2][S4][S8]
- Consolidated Funds quantum: Q1 2026 10-Q balance sheet detail [S3]
- 5th Circuit vacatur of SEC private fund rules: industry coverage [S15]

#### Assumption Register Updates

No new assumptions added. A10 (perf-fee comp ratio ~50%) and A20 (DE/equity ~25-30%) already capture key estimates.

#### Tables and Calculations

See GAAP-vs-non-GAAP bridge table and cash flow convergence table above.

#### Open Questions and Data Gaps

1. **SBC on a DE basis** — ARES (like peers) excludes from DE; the "true" cash-economic return is somewhat lower than headline DE per share
2. **GCP impairment risk** — Watch for any indicators in FY2026/2027 10-K MD&A
3. **Performance-fee comp ratio** — Industry estimates ~50%; actual is not always cleanly disclosed
4. **Consolidated Funds expansion** — Will continue to scale with CLO platform growth; not a problem per se but inflates GAAP-vs-economic divergence

#### Next-Step Dependencies

Step 06 (balance sheet & dilution) deepens the analysis of goodwill, intangibles, debt, and per-share dilution. Step 07 (capital allocation) examines the GCP deal in detail. Step 13 (forecast under `/complete-coverage`) will model FRE margin trajectory — any compression below 40% would be a thesis revision trigger.

#### Source Index

| Tag | Document or URL | Section / Page / Slide | Date | Notes |
|---|---|---|---|---|
| [S2] | ARES 10-K FY2025 | Notes 2 (acctg policies), 19 (segment), MD&A | 2026-02-25 | Auditor, statements, bridges |
| [S3] | SEC XBRL companyfacts | Balance sheet line items | 2026-05-28 | Consolidated Funds quantum |
| [S4] | ARES Q1 2026 Ex 99.2 | Reconciliations pp 18-22 | 2026-05-01 | Quarterly GAAP→non-GAAP |
| [S5] | ARES 10-K FY2024 | Note 12 Preferred Stock | 2025-02-27 | Series B mandatory convertible |
| [S8] | ARES Q4 2025 release | FY25 FRE margin 41.7% | 2026-02 | Margin compression context |
| [S10] | SEC Form 4 + insider trackers | 12-month activity | 2026-05-28 | 0 open-market buys (March 2026 drawdown) |
| [S11] | Fortune | "$265B private credit meltdown" | 2026-03-14 | Sector-wide adversarial narrative |
| [S15] | AGM Alts Weekly + industry coverage | 5th Circuit vacatur | 2024-mid | SEC private fund rules vacated |

## Recent Catalysts

---
ticker: ARES
step: 12
generated: 2026-05-28
source: coverage-next-full (transcript-free)
---

### ARES — Step 12: Bull vs Bear — Analyst Debate Synthesis

#### Key Findings

ARES sits at a **clear bull-vs-bear inflection** as of late May 2026: the **bull thesis** is durable ~20% AUM/DE CAGR, perpetual capital inflection through 40%+, Aspida flywheel maturation, and a record Q1 26 fundraising print [S4] vs the **bear thesis** of private-credit overcapacity / "$265B meltdown" multiple compression [S11], FRE margin creep risk, and Up-C/TRA cash leakage. The stock trades at **~14× P/DE** versus a peer median of **16-22×** [S12][S15] — implying the bear case is partly priced in, but not fully. **Consensus 12-month target is ~$179** (vs $108 spot in early May 2026 = ~66% upside) [S12] — sell-side modally constructive but with high dispersion. **The variant perception** (per Step 16) is that **the market is under-pricing ARES's perpetual capital inflection and Aspida flywheel** — these are slow-build optionality that compounds over 3-5 years. **Net constructive bias on the multi-year horizon, with credit-cycle clarity required for full conviction in the 12-month frame.**

#### Implications for Thesis and Valuation

1. **Probability-weighted scenarios:** Bull 35% × $200+ + Base 45% × $150-170 + Bear 20% × $90-110 = Expected value ~$155 (vs $108 spot ≈ +44%).
2. **Multi-year (3-5 year) thesis is stronger** than 12-month — perpetual capital + Aspida maturation are time-dependent value drivers.
3. **Entry timing matters** — at $108 the risk/reward is favorable but credit-cycle clarity (a few more quarters of fundraising data + private credit fund stability) would tighten the bear case.
4. **The bear case is largely sector-wide, not ARES-specific** — which both limits ARES-specific catalyst risk and means ARES rallies on sector recovery.
5. **Q4 26 / FY26 carry-harvest cycle** is the most material near-term catalyst — management has signaled FY26 should be a strong harvest year [S2].

#### Objective

Synthesize the bull-vs-bear analyst debate using filings, press releases, consensus commentary, and sector news (no transcripts loaded). Frame the debate so that Step 15 (scenarios under `/complete-coverage`) can build out the explicit scenario analysis.

#### Narrative Analysis

##### What the Bulls Believe

**Core bull thesis (composite from sell-side notes, public.com / etoro analyst views, AGM Alts Weekly [S12][S15]):**

1. **AUM growth at ~20% CAGR is durable** through FY28 — record Q1 26 fundraising ($29.5B) + shadow AUM ($80B+) + perpetual capital additions provide multi-year fee-revenue visibility [S4].

2. **Perpetual capital inflection** — moving from 32% (YE25) to management aspiration of 40%+ over 3-5 years would materially de-risk the fee base and warrant a higher multiple. The market has not fully priced this.

3. **FRE margin holds or expands** — currently 41-43%; operating leverage on incremental FPAUM at 80%+ marginal margin → FY27-28 FRE margin could reach 45%+.

4. **Aspida insurance flywheel** — sub-scale today (~$15-20B) vs APO/Athene ($300B+) but trajectory is right. At maturity, Aspida adds ~$300-500M of incremental annualized revenue.

5. **GCP integration delivers synergies** — FY26 first full year; cross-selling + scale benefits in Real Assets + Asia footprint creates incremental fee revenue.

6. **Capital allocation discipline** — 22% dividend CAGR, no goodwill impairments, accretive M&A track record.

7. **Multiple should re-rate** — ARES at 14× P/DE is below peer median 16-22×; sector recovery from the private-credit overhang should lift multiples toward 16-18× range.

**Bull case target:** $200+ (+85%+ upside from $108).

##### What the Bears Believe

**Core bear thesis (composite from Fortune coverage, Simply Wall Street margin-compression flags, bear-side sector commentary [S11][S15]):**

1. **Private credit cycle stress is real and worsening** — Fortune's "$265B meltdown" is the leading sector narrative; if specific ARES-managed funds run into NAV / redemption stress (none publicly identified yet, but ARES has $400B+ credit AUM = lots of fund-level potential exposure), multiples re-rate down sharply.

2. **Direct-lending spread compression** — 25-75 bps over 18-24 months means $300M-$700M revenue impact on a $300B+ direct-lending FPAUM base. Material to FRE.

3. **FRE margin compression risk** — Simply Wall Street flagged incentive comp ratio creep in Q1 26; if this trend continues, FRE margin could erode toward 38-40% over 4-6 quarters.

4. **Up-C / TRA cash leakage** — ~$50-100M/yr drag on cash-economic returns; DE overstates true returns to common.

5. **Insider activity neutral-to-negative** — 0 open-market buys during the March 2026 drawdown when stock was at ~$95 = no management conviction signal.

6. **Industry overcapacity is fundamental, not cyclical** — too much LP capital allocated to alts (~25% target vs ~10% historic); risk of LP allocation moderation if 1-2 years of mediocre returns materialize.

7. **Aspida lag vs APO/Athene** — ARES is materially behind the curve on insurance flywheel; this is not a near-term catalyst.

**Bear case target:** $90-110 (flat to -15% from $108).

##### Variant Perception (preview of Step 16)

**Market under-pricing:**
- Aspida flywheel maturation (3-5 year compounding)
- Perpetual capital % of AUM crossing 40% inflection
- Shadow AUM ($80B+) providing 12-18 months fee-revenue visibility
- GCP cross-selling synergies (FY26-27)

**Market over-pricing (i.e., bear is partially right):**
- ARES's resilience to private-credit cycle
- FRE margin sustainability at 42%+

The variant view: market is conflating ARES's sector-wide multiple compression with ARES-specific fundamental risk, when in fact ARES's fundamental drivers are intact and the perpetual capital / Aspida optionality is real.

##### Near-Term Catalysts (12-Month)

| Catalyst | Probability | Direction | Magnitude |
|---|---|---|---|
| Q2 26 / Q3 26 fundraising trajectory | High (Aug + Nov 2026 prints) | Positive if maintained | Medium |
| FY26 carry-harvest realization | Multi-quarter | Positive if delivered | High |
| Private-credit sector stability vs further stress | Q1-Q4 26 | Bidirectional | Very High |
| GCP synergies first-year evidence | Q4 26 / FY26 print | Positive if visible | Medium |
| Aspida AUM / contribution | Steady quarterly | Positive trajectory | Low-Medium |
| Macro / Fed rate trajectory | Ongoing | Modest negative | Low |
| Specific private credit fund stress at ARES | Tail | Negative if it occurs | Very High |

##### Consensus Frame

| Source | Target ($) | Rating Distribution |
|---|---|---|
| public.com / etoro aggregated | $179 (mean) | ~75% Buy / 20% Hold / 5% Sell [S12] |
| Range | $130 (low) — $230 (high) | High dispersion reflects bull/bear divide |
| ARES FY26E DE/sh consensus | ~$6.0-6.5 [A24] | — |
| Implied FY26E P/DE @ target | ~28× (high end) / ~22× (mean) | — |

Consensus expects multi-year multiple expansion AND DE/sh growth.

##### Synthesis

The bull and bear cases are both partially right. The bull's emphasis on durable platform fundamentals + perpetual capital inflection + Aspida flywheel is supported by Q1 26 data and the 3-5 year structural setup. The bear's emphasis on credit-cycle stress + FRE margin creep + multiple compression risk is supported by sector data and reasonable concerns about NAV / spread dynamics.

**The disagreement is largely about the time-horizon and resolution path:**
- Multi-year (3-5 years) — bulls have the edge on structural drivers
- 12-month (FY26) — heavily dependent on credit-cycle resolution

**Recommended stance (anticipating Step 18):** Constructive multi-year thesis at current ~$108; appropriate sizing reflects credit-cycle uncertainty; add aggressively on credit-cycle clarity or further weakness toward $90-100.

#### Evidence and Sources

- Private credit panic: Fortune March 2026 [S11]
- Q1 26 fundraising record: ARES Q1 26 release [S4]
- Consensus target + rating distribution: public.com / etoro / stockanalysis aggregated [S12]
- FRE margin trajectory: Q4 25 + Q1 26 releases [S4][S8]
- Margin compression watch: Simply Wall Street post-Q1 26 [S15]
- Insider activity: SEC Form 4 [S10]

#### Assumption Register Updates

Existing A25 (Bull case AUM CAGR 18-22%) and A26 (Bear case AUM CAGR 5-10%) anchor scenarios. No new entries.

#### Tables and Calculations

See bull thesis breakdown, bear thesis breakdown, catalyst table, and consensus frame above.

#### Open Questions and Data Gaps

1. **Magnitude of any specific ARES-managed credit fund stress** — None publicly identified but ARES manages 200+ funds; tail risk exists
2. **GCP synergy quantification** — Will not be fully visible until late FY26
3. **Fed rate cut path** — Currently ~150 bps of cuts priced in FY26; outcome uncertain
4. **LP allocation shift in 2026-2027** — Sustainability of ~25% target allocation TBD

#### Next-Step Dependencies

Step 16 (variant perception) deepens the under-pricing and over-pricing analysis. Step 15 (scenarios under `/complete-coverage`) builds explicit quantitative scenarios. Step 18 (portfolio fit) translates bull-bear synthesis into position sizing and entry-timing recommendations.

#### Source Index

| Tag | Document or URL | Section / Page / Slide | Date | Notes |
|---|---|---|---|---|
| [S2] | ARES 10-K FY2025 | MD&A forward commentary | 2026-02-25 | FY26 harvest cycle framing |
| [S4] | ARES Q1 2026 Ex 99.2 | Q1 26 print | 2026-05-01 | Fundraising record + FRE momentum |
| [S8] | ARES Q4 2025 release | Q4 25 miss + FY25 results | 2026-02 | Bear-side data point |
| [S10] | SEC Form 4 + insider trackers | T12M activity | 2026-05-28 | Insider buy = 0 signal |
| [S11] | Fortune | "$265B private credit meltdown" | 2026-03-14 | Bear narrative source |
| [S12] | Street consensus aggregated | public.com / etoro | 2026-05 | Target + rating distribution |
| [S15] | AGM Alts Weekly + Simply Wall Street | Industry + margin watch | 2026-05 | Bull + bear synthesis context |

---

#### Bull Case — 3 bullets

1. **Durable ~20% AUM / DE CAGR through FY28.** Record Q1 26 fundraising ($29.5B, +48% YoY) + $80B+ shadow AUM + perpetual capital additions provide multi-year fee-revenue visibility. FRE +26% YoY at $464.4M shows operating leverage intact [S4]. AUM trajectory to ~$1T over 3-5 years is plausible.

2. **Perpetual capital inflection 32% → 40%+ over 3-5 years would warrant a 20%+ multiple re-rating.** ARES currently trades at ~14× P/DE vs peer median 16-22×; OWL at 80% perpetual capital trades at 22× — the perpetual capital math drives sustained re-rating [S12][S15]. Aspida flywheel ($15-20B → $40-50B+) adds incremental durable revenue.

3. **GCP synergies + Asia momentum + carry-harvest cycle hit in FY26.** First full year of GCP International contribution doubles Real Assets AUM impact; carry-harvest cycle expected to be strong; cross-selling between ARES and GCP LP bases delivers additional fundraising tailwind. Capital allocation discipline (22% dividend CAGR, no impairments, accretive M&A) supports the thesis [S2][S14].

#### Bear Case — 3 bullets

1. **Private credit cycle stress and the "$265B meltdown" narrative compress multiples sector-wide.** Direct-lending spread compression of 25-75 bps over 18-24 months → $300M-$700M revenue impact on $300B+ direct-lending FPAUM base; LP allocation appetite could moderate if 1-2 years of mediocre sector returns materialize. ARES at 14× P/DE may re-rate down further toward 11-13× if specific ARES-managed credit funds run into NAV / redemption stress [S11][A23].

2. **FRE margin compression from rising incentive comp ratios.** Simply Wall Street flagged Q1 26 incentive comp ratio creep — if this trend continues, FRE margin could erode from 41-43% toward 38-40% over 4-6 quarters, materially compressing the operating leverage thesis [S15]. The Q4 25 miss already showed performance harvest timing variance is a real downside risk.

3. **Up-C / TRA cash leakage + lack of insider conviction signal mild bear.** ~$50-100M/yr TRA payments are real cash drag that DE overstates; ongoing AOG unit exchanges + ~$1B Series B Preferred conversion add per-share dilution; insider 0 open-market buys during the March 2026 drawdown when stock traded ~$95 = no management conviction signal at currently mid-range valuation [S9][S10]. Aspida lag vs APO/Athene means insurance flywheel is not a near-term catalyst.

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/ares
- Full research API: GET /api/v1/research/ARES/memo
- Coverage universe: /stocks